{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:30:48Z","timestamp":1791462648575,"version":"4.3.4"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002426","name":"Fondazione Telethon","doi-asserted-by":"publisher","award":["GMR22T1081"],"award-info":[{"award-number":["GMR22T1081"]}],"id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["30318"],"award-info":[{"award-number":["30318"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["101078646"],"award-info":[{"award-number":["101078646"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"DOI":"10.1007\/s00018-026-06135-y","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:47:09Z","timestamp":1773683229000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Identification of alterations of immunometabolism associated with Pompe disease"],"prefix":"10.1007","volume":"83","author":[{"given":"Helena","family":"Costa-Verdera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Gargaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umut","family":"Cagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Manni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Scalisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Veron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estev\u00e3o Carlos","family":"Silva Barcelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Pieroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Mencarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doriana","family":"Ricciuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Nemazanyy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Sanatine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"van Wittenberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Lafor\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David-Alexandre","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ronzitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Fallarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9658-6466","authenticated-orcid":false,"given":"Federico","family":"Mingozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"6135_CR1","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/s0002-9440(10)65361-8","volume":"154","author":"E Ponce","year":"1999","unstructured":"Ponce E, Witte DP, Hirschhorn R, Huie ML, Grabowski GA (1999) Murine acid alpha-glucosidase: cell-specific mRNA differential expression during development and maturation. Am J Pathol 154:1089\u20131096. https:\/\/doi.org\/10.1016\/s0002-9440(10)65361-8","journal-title":"Am J Pathol"},{"key":"6135_CR2","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/S0021-9258(18)53985-5","volume":"268","author":"HA Wisselaar","year":"1993","unstructured":"Wisselaar HA, Kroos MA, Hermans MM, van Beeumen J (1993) Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation. J Biol Chem 268:2223\u20132231","journal-title":"J Biol Chem"},{"key":"6135_CR3","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ymthe.2006.08.009","volume":"14","author":"T Fukuda","year":"2006","unstructured":"Fukuda T, Ahearn M, Roberts A, Mattaliano RJ, Zaal K, Ralston E, Plotz PH, Raben N (2006) Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease. Mol Ther 14:831\u2013839. https:\/\/doi.org\/10.1016\/j.ymthe.2006.08.009","journal-title":"Mol Ther"},{"key":"6135_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-90","volume":"8","author":"SN Prater","year":"2013","unstructured":"Prater SN, Patel TT, Buckley AF, Mandel H, Vlodavski E, Banugaria SG, Feeney EJ, Raben N, Kishnani PS (2013) Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy. Orphanet J Rare Dis 8:90. https:\/\/doi.org\/10.1186\/1750-1172-8-90","journal-title":"Orphanet J Rare Dis"},{"key":"6135_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2174\/1566524024605789","volume":"2","author":"N Raben","year":"2002","unstructured":"Raben N, Plotz P, Byrne BJ (2002) Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr Mol Med 2:145\u2013166","journal-title":"Curr Mol Med"},{"key":"6135_CR6","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1542\/peds.112.2.332","volume":"112","author":"HM van den Hout","year":"2003","unstructured":"van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, Poll-The BT, Bakker HD, Loonen MC, de Klerk JB, Reuser AJ, van der Ploeg AT (2003) The natural course of infantile Pompe\u2019s disease: 20 original cases compared with 133 cases from the literature. Pediatrics 112:332\u2013340. https:\/\/doi.org\/10.1542\/peds.112.2.332","journal-title":"Pediatrics"},{"key":"6135_CR7","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","volume":"148","author":"PS Kishnani","year":"2006","unstructured":"Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D, Infantile-Onset Pompe Disease Natural History Study, G (2006) A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148:671\u2013676. https:\/\/doi.org\/10.1016\/j.jpeds.2005.11.033","journal-title":"J Pediatr"},{"key":"6135_CR8","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1212\/wnl.55.8.1122","volume":"55","author":"P Lafor\u00eat","year":"2000","unstructured":"Lafor\u00eat P, Nicolino M, Eymard B, Puech JP, Caillaud C, Poenaru L, Fardeau M (2000) Juvenile and adult-onset acid maltase deficiency in France. Genotype\u2013phenotype correlation. Neurology 55:1122\u20131128. https:\/\/doi.org\/10.1212\/wnl.55.8.1122","journal-title":"Neurology"},{"key":"6135_CR9","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1097\/NEN.0b013e3181815994","volume":"67","author":"RL Sidman","year":"2008","unstructured":"Sidman RL, Taksir T, Fidler J, Zhao M, Dodge JC, Passini MA, Raben N, Thurberg BL, Cheng SH, Shihabuddin LS (2008) Temporal neuropathologic and behavioral phenotype of 6neo\/6neo Pompe disease mice. J Neuropathol Exp Neurol 67:803\u2013818. https:\/\/doi.org\/10.1097\/NEN.0b013e3181815994","journal-title":"J Neuropathol Exp Neurol"},{"key":"6135_CR10","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/j.jpeds.2004.01.053","volume":"144","author":"PS Kishnani","year":"2004","unstructured":"Kishnani PS, Howell RR (2004) Pompe disease in infants and children. J Pediatr 144:S35-43. https:\/\/doi.org\/10.1016\/j.jpeds.2004.01.053","journal-title":"J Pediatr"},{"key":"6135_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/ajmg.c.31318","volume":"160C","author":"M Kroos","year":"2012","unstructured":"Kroos M, Hoogeveen-Westerveld M, van der Ploeg A, Reuser AJ (2012) The genotype-phenotype correlation in Pompe disease. Am J Med Genet C Semin Med Genet 160C:59\u201368. https:\/\/doi.org\/10.1002\/ajmg.c.31318","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"6135_CR12","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/ana.20807","volume":"59","author":"T Fukuda","year":"2006","unstructured":"Fukuda T, Ewan L, Bauer M, Mattaliano RJ, Zaal K, Ralston E, Plotz PH, Raben N (2006) Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease. Ann Neurol 59:700\u2013708. https:\/\/doi.org\/10.1002\/ana.20807","journal-title":"Ann Neurol"},{"key":"6135_CR13","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/labinvest.3700484","volume":"86","author":"BL Thurberg","year":"2006","unstructured":"Thurberg BL, Lynch Maloney C, Vaccaro C, Afonso K, Tsai AC, Bossen E, Kishnani PS, O\u2019Callaghan M (2006) Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest 86:1208\u20131220. https:\/\/doi.org\/10.1038\/labinvest.3700484","journal-title":"Lab Invest"},{"key":"6135_CR14","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1038\/cdd.2012.52","volume":"19","author":"AC Nascimbeni","year":"2012","unstructured":"Nascimbeni AC, Fanin M, Masiero E, Angelini C, Sandri M (2012) The role of autophagy in the pathogenesis of glycogen storage disease type II (GSDII). Cell Death Differ 19:1698\u20131708. https:\/\/doi.org\/10.1038\/cdd.2012.52","journal-title":"Cell Death Differ"},{"key":"6135_CR15","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1093\/hmg\/ddn292","volume":"17","author":"N Raben","year":"2008","unstructured":"Raben N, Hill V, Shea L, Takikita S, Baum R, Mizushima N, Ralston E, Plotz P (2008) Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease. Hum Mol Genet 17:3897\u20133908. https:\/\/doi.org\/10.1093\/hmg\/ddn292","journal-title":"Hum Mol Genet"},{"key":"6135_CR16","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1016\/j.ymthe.2020.05.025","volume":"28","author":"U Cagin","year":"2020","unstructured":"Cagin U, Puzzo F, Gomez MJ, Moya-Nilges M, Sellier P, Abad C, Van Wittenberghe L, Daniele N, Guerchet N, Gjata B et al (2020) Rescue of advanced pompe disease in mice with hepatic expression of secretable acid alpha-glucosidase. Mol Ther 28:2056\u20132072. https:\/\/doi.org\/10.1016\/j.ymthe.2020.05.025","journal-title":"Mol Ther"},{"key":"6135_CR17","doi-asserted-by":"publisher","first-page":"eaam6375","DOI":"10.1126\/scitranslmed.aam6375","volume":"9","author":"F Puzzo","year":"2017","unstructured":"Puzzo F, Colella P, Biferi MG, Bali D, Paulk NK, Vidal P, Collaud F, Simon-Sola M, Charles S, Hardet R et al (2017) Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid alpha-glucosidase. Sci Transl Med 9:eaam6375. https:\/\/doi.org\/10.1126\/scitranslmed.aam6375","journal-title":"Sci Transl Med"},{"key":"6135_CR18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/15548627.2015.1009779","volume":"11","author":"J-A Lim","year":"2015","unstructured":"Lim J-A, Li L, Kakhlon O, Myerowitz R, Raben N (2015) Defects in calcium homeostasis and mitochondria can be reversed in Pompe disease. Autophagy 11:385\u2013402. https:\/\/doi.org\/10.1080\/15548627.2015.1009779","journal-title":"Autophagy"},{"key":"6135_CR19","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1111\/febs.14468","volume":"285","author":"M Lahuerta","year":"2018","unstructured":"Lahuerta M, Aguado C, S\u00e1nchez-Mart\u00edn P, Sanz P, Knecht E (2018) Degradation of altered mitochondria by autophagy is impaired in Lafora disease. FEBS J 285:2071\u20132090. https:\/\/doi.org\/10.1111\/febs.14468","journal-title":"FEBS J"},{"key":"6135_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","volume":"68","author":"PS Kishnani","year":"2007","unstructured":"Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, Leslie N, Levine J, Spencer C, McDonald M et al (2007) Recombinant human acid \u03b1-glucosidase. Major clinical benefits in infantile-onset Pompe disease. Neurology 68:99\u2013109. https:\/\/doi.org\/10.1212\/01.wnl.0000251268.41188.04","journal-title":"Neurology"},{"key":"6135_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jpeds.2006.02.035","volume":"149","author":"PS Kishnani","year":"2006","unstructured":"Kishnani PS, Nicolino M, Voit T, Rogers RC, Tsai AC, Waterson J, Herman GE, Amalfitano A, Thurberg BL, Richards S et al (2006) Chinese hamster ovary cell-derived recombinant human acid \u03b1-glucosidase in infantile-onset Pompe disease. J Pediatr 149:89\u201397. https:\/\/doi.org\/10.1016\/j.jpeds.2006.02.035","journal-title":"J Pediatr"},{"key":"6135_CR22","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/0883073807302598","volume":"22","author":"M Rossi","year":"2007","unstructured":"Rossi M, Parenti G, Della Casa R, Romano A, Mansi G, Agovino T, Rosapepe F, Vosa C, Del Giudice E, Andria G (2007) Long-term enzyme replacement therapy for pompe disease with recombinant human alpha-glucosidase derived from Chinese hamster ovary cells. J Child Neurol 22:565\u2013573. https:\/\/doi.org\/10.1177\/0883073807302598","journal-title":"J Child Neurol"},{"key":"6135_CR23","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00246-008-9267-3","volume":"29","author":"JC Levine","year":"2008","unstructured":"Levine JC, Kishnani PS, Chen YT, Herlong JR, Li JS (2008) Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease. Pediatr Cardiol 29:1033\u20131042. https:\/\/doi.org\/10.1007\/s00246-008-9267-3","journal-title":"Pediatr Cardiol"},{"key":"6135_CR24","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","volume":"362","author":"AT van der Ploeg","year":"2010","unstructured":"van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, Herson S, Kishnani PS, Laforet P, Lake SL et al (2010) A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease. N Engl J Med 362:1396\u20131406. https:\/\/doi.org\/10.1056\/NEJMoa0909859","journal-title":"N Engl J Med"},{"key":"6135_CR25","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ymgme.2012.09.015","volume":"107","author":"AT van der Ploeg","year":"2012","unstructured":"van der Ploeg AT, Barohn R, Carlson L, Charrow J, Clemens PR, Hopkin RJ, Kishnani PS, Lafor\u00eat P, Morgan C, Nations S et al (2012) Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. Mol Genet Metab 107:456\u2013461. https:\/\/doi.org\/10.1016\/j.ymgme.2012.09.015","journal-title":"Mol Genet Metab"},{"key":"6135_CR26","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/gim200127","volume":"3","author":"A Amalfitano","year":"2001","unstructured":"Amalfitano A, Bengur AR, Morse RP, Majure JM, Case LE, Veerling DL, Mackey J, Kishnani P, Smith W, McVie-Wylie A et al (2001) Recombinant human acid \u03b1-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I\/II clinical trial. Genet Med 3:132\u2013138. https:\/\/doi.org\/10.1038\/gim200127","journal-title":"Genet Med"},{"key":"6135_CR27","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jpeds.2013.03.002","volume":"163","author":"ME Elder","year":"2013","unstructured":"Elder ME, Nayak S, Collins SW, Lawson LA, Kelley JS, Herzog RW, Modica RF, Lew J, Lawrence RM, Byrne BJ (2013) B-cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 163:847\u2013854. https:\/\/doi.org\/10.1016\/j.jpeds.2013.03.002","journal-title":"J Pediatr"},{"key":"6135_CR28","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1038\/sj.gt.3302314","volume":"11","author":"F Xu","year":"2004","unstructured":"Xu F, Ding E, Liao SX, Migone F, Dai J, Schneider A, Serra D, Chen YT, Amalfitano A (2004) Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model. Gene Ther 11:1590\u20131598. https:\/\/doi.org\/10.1038\/sj.gt.3302314","journal-title":"Gene Ther"},{"key":"6135_CR29","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/gim.2015.6","volume":"17","author":"KL Berrier","year":"2015","unstructured":"Berrier KL, Kazi ZB, Prater SN, Bali DS, Goldstein J, Stefanescu MC, Rehder CW, Botha EG, Ellaway C, Bhattacharya K et al (2015) CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy. Genet Med 17:912\u2013918. https:\/\/doi.org\/10.1038\/gim.2015.6","journal-title":"Genet Med"},{"key":"6135_CR30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","volume":"99","author":"PS Kishnani","year":"2010","unstructured":"Kishnani PS, Goldenberg PC, DeArmey SL, Heller J, Benjamin D, Young S, Bali D, Smith SA, Li JS, Mandel H et al (2010) Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 99:26\u201333. https:\/\/doi.org\/10.1016\/j.ymgme.2009.08.003","journal-title":"Mol Genet Metab"},{"key":"6135_CR31","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ymgme.2010.08.009","volume":"101","author":"JM de Vries","year":"2010","unstructured":"de Vries JM, van der Beek NA, Kroos MA, Ozkan L, van Doorn PA, Richards SM, Sung CC, Brugma JD, Zandbergen AA, van der Ploeg AT, Reuser AJ (2010) High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genet Metab 101:338\u2013345. https:\/\/doi.org\/10.1016\/j.ymgme.2010.08.009","journal-title":"Mol Genet Metab"},{"key":"6135_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2019.100475","volume":"20","author":"AK Desai","year":"2019","unstructured":"Desai AK, Kazi ZB, Bali DS, Kishnani PS (2019) Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy. Mol Genet Metab Rep 20:100475. https:\/\/doi.org\/10.1016\/j.ymgmr.2019.100475","journal-title":"Mol Genet Metab Rep"},{"key":"6135_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2015.53","volume":"3","author":"PA Doerfler","year":"2016","unstructured":"Doerfler PA, Nayak S, Corti M, Morel L, Herzog RW, Byrne BJ (2016) Targeted approaches to induce immune tolerance for Pompe disease therapy. Molecular Therapy - Methods & Clinical Development 3:15053. https:\/\/doi.org\/10.1038\/mtm.2015.53","journal-title":"Molecular Therapy - Methods & Clinical Development"},{"key":"6135_CR34","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94328","volume":"2","author":"ZB Kazi","year":"2017","unstructured":"Kazi ZB, Desai AK, Berrier KL, Troxler RB, Wang RY, Abdul-Rahman OA, Tanpaiboon P, Mendelsohn NJ, Herskovitz E, Kronn D et al (2017) Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease. JCI Insight 2:e94328. https:\/\/doi.org\/10.1172\/jci.insight.94328","journal-title":"JCI Insight"},{"key":"6135_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.107611","volume":"139","author":"LER Lessard","year":"2023","unstructured":"Lessard LER, Tard C, Salort-Campana E, Sacconi S, B\u00e9hin A, Bassez G, Orlikowski D, Merle P, Nollet S, Gallay L et al (2023) Hypersensitivity infusion-associated reactions induced by enzyme replacement therapy in a cohort of patients with late-onset Pompe disease: an experience from the French Pompe Registry. Mol Genet Metab 139:107611. https:\/\/doi.org\/10.1016\/j.ymgme.2023.107611","journal-title":"Mol Genet Metab"},{"key":"6135_CR36","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.anai.2020.07.010","volume":"125","author":"I Turgay Yagmur","year":"2020","unstructured":"Turgay Yagmur I, Unal Uzun O, Kucukcongar Yavas A, Kulhas Celik I, Toyran M, Gunduz M, Civelek E, Dibek Misirlioglu E (2020) Management of hypersensitivity reactions to enzyme replacement therapy in children with lysosomal storage diseases. Ann Allergy Asthma Immunol 125:460\u2013467. https:\/\/doi.org\/10.1016\/j.anai.2020.07.010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"6135_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1336599","volume":"15","author":"HA Chen","year":"2024","unstructured":"Chen HA, Hsu RH, Fang CY, Desai AK, Lee NC, Hwu WL, Tsai FJ, Kishnani PS, Chien YH (2024) Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy. Front Immunol 15:1336599. https:\/\/doi.org\/10.3389\/fimmu.2024.1336599","journal-title":"Front Immunol"},{"key":"6135_CR38","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/15548627.2015.1009779","volume":"11","author":"JA Lim","year":"2015","unstructured":"Lim JA, Li L, Kakhlon O, Myerowitz R, Raben N (2015) Defects in calcium homeostasis and mitochondria can be reversed in Pompe disease. Autophagy 11:385\u2013402. https:\/\/doi.org\/10.1080\/15548627.2015.1009779","journal-title":"Autophagy"},{"key":"6135_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41556-017-0002-2","volume":"20","author":"R Ma","year":"2018","unstructured":"Ma R, Ji T, Zhang H, Dong W, Chen X, Xu P, Chen D, Liang X, Yin X, Liu Y et al (2018) A Pck1-directed glycogen metabolic program regulates formation and maintenance of memory CD8(+) T cells. Nat Cell Biol 20:21\u201327. https:\/\/doi.org\/10.1038\/s41556-017-0002-2","journal-title":"Nat Cell Biol"},{"key":"6135_CR40","doi-asserted-by":"publisher","first-page":"7349","DOI":"10.4049\/jimmunol.1000576","volume":"185","author":"VM Hubbard","year":"2010","unstructured":"Hubbard VM, Valdor R, Patel B, Singh R, Cuervo AM, Macian F (2010) Macroautophagy regulates energy metabolism during effector T cell activation. J Immunol 185:7349\u20137357. https:\/\/doi.org\/10.4049\/jimmunol.1000576","journal-title":"J Immunol"},{"key":"6135_CR41","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.4049\/jimmunol.0801143","volume":"182","author":"HH Pua","year":"2009","unstructured":"Pua HH, Guo J, Komatsu M, He Y-W (2009) Autophagy is essential for mitochondrial clearance in mature T lymphocytes. J Immunol 182:4046\u20134055. https:\/\/doi.org\/10.4049\/jimmunol.0801143","journal-title":"J Immunol"},{"key":"6135_CR42","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41586-018-0846-z","volume":"565","author":"SE Weinberg","year":"2019","unstructured":"Weinberg SE, Singer BD, Steinert EM, Martinez CA, Mehta MM, Martinez-Reyes I, Gao P, Helmin KA, Abdala-Valencia H, Sena LA et al (2019) Mitochondrial complex III is essential for suppressive function of regulatory T cells. Nature 565:495\u2013499. https:\/\/doi.org\/10.1038\/s41586-018-0846-z","journal-title":"Nature"},{"key":"6135_CR43","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/ni.3365","volume":"17","author":"J Wei","year":"2016","unstructured":"Wei J, Long L, Yang K, Guy C, Shrestha S, Chen Z, Wu C, Vogel P, Neale G, Green DR, Chi H (2016) Autophagy enforces functional integrity of regulatory T cells by coupling environmental cues and metabolic homeostasis. Nat Immunol 17:277\u2013285. https:\/\/doi.org\/10.1038\/ni.3365","journal-title":"Nat Immunol"},{"key":"6135_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00775","volume":"10","author":"SK Wculek","year":"2019","unstructured":"Wculek SK, Khouili SC, Priego E, Heras-Murillo I, Sancho D (2019) Metabolic control of dendritic cell functions: digesting information. Front Immunol 10:775. https:\/\/doi.org\/10.3389\/fimmu.2019.00775","journal-title":"Front Immunol"},{"key":"6135_CR45","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10545-009-9027-4","volume":"33","author":"MLC Hagemans","year":"2010","unstructured":"Hagemans MLC, Stigter RL, van Capelle CI, van der Beek NAME, Winkel LPF, van Vliet L, Hop WCJ, Reuser AJJ, Beishuizen A, van der Ploeg AT (2010) PAS-positive lymphocyte vacuoles can be used as diagnostic screening test for Pompe disease. J Inherit Metab Dis 33:133\u2013139. https:\/\/doi.org\/10.1007\/s10545-009-9027-4","journal-title":"J Inherit Metab Dis"},{"key":"6135_CR46","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.1002\/jcp.26365","volume":"233","author":"A Pascarella","year":"2018","unstructured":"Pascarella A, Terracciano C, Farina O, Lombardi L, Esposito T, Napolitano F, Franzese G, Panella G, Tuccillo F, la Marca G et al (2018) Vacuolated PAS-positive lymphocytes as an hallmark of Pompe disease and other myopathies related to impaired autophagy. J Cell Physiol 233:5829\u20135837. https:\/\/doi.org\/10.1002\/jcp.26365","journal-title":"J Cell Physiol"},{"key":"6135_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/srep36182","volume":"6","author":"E Masat","year":"2016","unstructured":"Masat E, Laforet P, De Antonio M, Corre G, Perniconi B, Taouagh N, Mariampillai K, Amelin D, Mauhin W, Hogrel JY et al (2016) Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients. Sci Rep 6:36182. https:\/\/doi.org\/10.1038\/srep36182","journal-title":"Sci Rep"},{"key":"6135_CR48","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.neurol.2013.07.002","volume":"169","author":"P Lafor\u00eat","year":"2013","unstructured":"Lafor\u00eat P, Laloui K, Granger B, Hamroun D, Taouagh N, Hogrel JY, Orlikowski D, Bouhour F, Lacour A, Salort-Campana E et al (2013) The French Pompe registry. Baseline characteristics of a cohort of 126 patients with adult Pompe disease. Rev Neurol (Paris) 169:595\u2013602. https:\/\/doi.org\/10.1016\/j.neurol.2013.07.002","journal-title":"Rev Neurol (Paris)"},{"key":"6135_CR49","doi-asserted-by":"publisher","first-page":"19086","DOI":"10.1074\/jbc.273.30.19086","volume":"273","author":"N Raben","year":"1998","unstructured":"Raben N, Nagaraju K, Lee E, Kessler P, Byrne B, Lee L, LaMarca M, King C, Ward J, Sauer B, Plotz P (1998) Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J Biol Chem 273:19086\u201319092. https:\/\/doi.org\/10.1074\/jbc.273.30.19086","journal-title":"J Biol Chem"},{"key":"6135_CR50","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.immuni.2022.05.013","volume":"55","author":"M Gargaro","year":"2022","unstructured":"Gargaro M, Scalisi G, Manni G, Brise\u00f1o CG, Bagadia P, Durai V, Theisen DJ, Kim S, Castelli M, Xu CA et al (2022) Indoleamine 2,3-dioxygenase 1 activation in mature cDC1 promotes tolerogenic education of inflammatory cDC2 via metabolic communication. Immunity 55:1032-1050.e1014. https:\/\/doi.org\/10.1016\/j.immuni.2022.05.013","journal-title":"Immunity"},{"key":"6135_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1182553","volume":"14","author":"S Zhang","year":"2023","unstructured":"Zhang S, Audiger C, Chopin M, Nutt SL (2023) Transcriptional regulation of dendritic cell development and function. Front Immunol 14:1182553. https:\/\/doi.org\/10.3389\/fimmu.2023.1182553","journal-title":"Front Immunol"},{"key":"6135_CR52","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler A, Hoffman P, Smibert P, Papalexi E, Satija R (2018) Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol 36:411\u2013420. https:\/\/doi.org\/10.1038\/nbt.4096","journal-title":"Nat Biotechnol"},{"key":"6135_CR53","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","volume":"8","author":"CS McGinnis","year":"2019","unstructured":"McGinnis CS, Murrow LM, Gartner ZJ (2019) DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst 8:329-337.e324. https:\/\/doi.org\/10.1016\/j.cels.2019.03.003","journal-title":"Cell Syst"},{"key":"6135_CR54","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, Baglaenko Y, Brenner M, Loh P-R, Raychaudhuri S (2019) Fast, sensitive and accurate integration of single-cell data with Harmony. Nat Methods 16:1289\u20131296. https:\/\/doi.org\/10.1038\/s41592-019-0619-0","journal-title":"Nat Methods"},{"key":"6135_CR55","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran D, Looney AP, Liu L, Wu E, Fong V, Hsu A, Chak S, Naikawadi RP, Wolters PJ, Abate AR et al (2019) Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol 20:163\u2013172. https:\/\/doi.org\/10.1038\/s41590-018-0276-y","journal-title":"Nat Immunol"},{"key":"6135_CR56","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.celrep.2018.01.040","volume":"22","author":"AV Menk","year":"2018","unstructured":"Menk AV, Scharping NE, Moreci RS, Zeng X, Guy C, Salvatore S, Bae H, Xie J, Young HA, Wendell SG, Delgoffe GM (2018) Early TCR signaling induces rapid aerobic glycolysis enabling distinct acute T cell effector functions. Cell Rep 22:1509\u20131521. https:\/\/doi.org\/10.1016\/j.celrep.2018.01.040","journal-title":"Cell Rep"},{"key":"6135_CR57","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.omtm.2018.11.002","volume":"12","author":"P Colella","year":"2018","unstructured":"Colella P, Sellier P, Costa Verdera H, Puzzo F, van Wittenberghe L, Guerchet N, Daniele N, Gjata B, Marmier S, Charles S et al (2018) AAV gene transfer with tandem promoter design prevents anti-transgene immunity and provides persistent efficacy in neonate Pompe mice. Mol Ther Methods Clin Dev 12:85\u2013101. https:\/\/doi.org\/10.1016\/j.omtm.2018.11.002","journal-title":"Mol Ther Methods Clin Dev"},{"key":"6135_CR58","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.omtm.2020.05.026","volume":"18","author":"NK Meena","year":"2020","unstructured":"Meena NK, Ralston E, Raben N, Puertollano R (2020) Enzyme replacement therapy can reverse pathogenic cascade in Pompe disease. Mol Ther Methods Clin Dev 18:199\u2013214. https:\/\/doi.org\/10.1016\/j.omtm.2020.05.026","journal-title":"Mol Ther Methods Clin Dev"},{"key":"6135_CR59","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.cmet.2015.07.020","volume":"22","author":"F Baixauli","year":"2015","unstructured":"Baixauli F, Acin-Perez R, Villarroya-Beltri C, Mazzeo C, Nunez-Andrade N, Gabande-Rodriguez E, Ledesma MD, Blazquez A, Martin MA, Falcon-Perez JM et al (2015) Mitochondrial respiration controls lysosomal function during inflammatory T cell responses. Cell Metab 22:485\u2013498. https:\/\/doi.org\/10.1016\/j.cmet.2015.07.020","journal-title":"Cell Metab"},{"key":"6135_CR60","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cell.2016.05.035","volume":"166","author":"MD Buck","year":"2016","unstructured":"Buck MD, O\u2019Sullivan D, Klein Geltink RI, Curtis JD, Chang CH, Sanin DE, Qiu J, Kretz O, Braas D, van der Windt GJ et al (2016) Mitochondrial dynamics controls T cell fate through metabolic programming. Cell 166:63\u201376. https:\/\/doi.org\/10.1016\/j.cell.2016.05.035","journal-title":"Cell"},{"key":"6135_CR61","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.4049\/jimmunol.1202071","volume":"190","author":"VV Parekh","year":"2013","unstructured":"Parekh VV, Wu L, Boyd KL, Williams JA, Gaddy JA, Olivares-Villagomez D, Cover TL, Zong WX, Zhang J, Van Kaer L (2013) Impaired autophagy, defective T cell homeostasis, and a wasting syndrome in mice with a T cell-specific deletion of Vps34. J Immunol 190:5086\u20135101. https:\/\/doi.org\/10.4049\/jimmunol.1202071","journal-title":"J Immunol"},{"key":"6135_CR62","doi-asserted-by":"publisher","first-page":"353","DOI":"10.15252\/emmm.201606547","volume":"9","author":"JA Lim","year":"2017","unstructured":"Lim JA, Li L, Shirihai OS, Trudeau KM, Puertollano R, Raben N (2017) Modulation of mTOR signaling as a strategy for the treatment of Pompe disease. EMBO Mol Med 9:353\u2013370. https:\/\/doi.org\/10.15252\/emmm.201606547","journal-title":"EMBO Mol Med"},{"key":"6135_CR63","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1139","volume":"9","author":"Y Ye","year":"2020","unstructured":"Ye Y, Gaugler B, Mohty M, Malard F (2020) Plasmacytoid dendritic cell biology and its role in immune-mediated diseases. Clin Transl Immunol 9:e1139. https:\/\/doi.org\/10.1002\/cti2.1139","journal-title":"Clin Transl Immunol"},{"key":"6135_CR64","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/ni1522","volume":"8","author":"SH Naik","year":"2007","unstructured":"Naik SH, Sathe P, Park H-Y, Metcalf D, Proietto AI, Dakic A, Carotta S, O\u2019Keeffe M, Bahlo M, Papenfuss A et al (2007) Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo. Nat Immunol 8:1217\u20131226. https:\/\/doi.org\/10.1038\/ni1522","journal-title":"Nat Immunol"},{"key":"6135_CR65","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1084\/jem.20030107","volume":"198","author":"A D\u2019Amico","year":"2003","unstructured":"D\u2019Amico A, Wu L (2003) The early progenitors of mouse dendritic cells and plasmacytoid predendritic cells are within the bone marrow hemopoietic precursors expressing Flt3. J Exp Med 198:293\u2013303. https:\/\/doi.org\/10.1084\/jem.20030107","journal-title":"J Exp Med"},{"key":"6135_CR66","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1189\/jlb.0104037","volume":"76","author":"U Ritter","year":"2004","unstructured":"Ritter U, Wiede F, Mielenz D, Kiafard Z, Zwirner J, K\u00f6rner H (2004) Analysis of the CCR7 expression on murine bone marrow-derived and spleen dendritic cells. J Leukoc Biol 76:472\u2013476. https:\/\/doi.org\/10.1189\/jlb.0104037","journal-title":"J Leukoc Biol"},{"key":"6135_CR67","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.4049\/jimmunol.161.6.3096","volume":"161","author":"S Yanagihara","year":"1998","unstructured":"Yanagihara S, Komura E, Nagafune J, Watarai H, Yamaguchi Y (1998) EBI1\/CCR7 is a new member of dendritic cell chemokine receptor that is up-regulated upon maturation. J Immunol 161:3096\u20133102","journal-title":"J Immunol"},{"key":"6135_CR68","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nature13323","volume":"511","author":"A Bessede","year":"2014","unstructured":"Bessede A, Gargaro M, Pallotta MT, Matino D, Servillo G, Brunacci C, Bicciato S, Mazza EM, Macchiarulo A, Vacca C et al (2014) Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature 511:184\u2013190. https:\/\/doi.org\/10.1038\/nature13323","journal-title":"Nature"},{"key":"6135_CR69","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.4049\/jimmunol.173.7.4433","volume":"173","author":"EA Moseman","year":"2004","unstructured":"Moseman EA, Liang X, Dawson AJ, Panoskaltsis-Mortari A, Krieg AM, Liu Y-J, Blazar BR, Chen W (2004) Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells1. J Immunol 173:4433\u20134442. https:\/\/doi.org\/10.4049\/jimmunol.173.7.4433","journal-title":"J Immunol"},{"key":"6135_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2874","volume":"4","author":"C Volpi","year":"2013","unstructured":"Volpi C, Fallarino F, Pallotta MT, Bianchi R, Vacca C, Belladonna ML, Orabona C, De Luca A, Boon L, Romani L et al (2013) High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9-TRIF pathway. Nat Commun 4:1852. https:\/\/doi.org\/10.1038\/ncomms2874","journal-title":"Nat Commun"},{"key":"6135_CR71","doi-asserted-by":"publisher","unstructured":"Krug A, Rothenfusser S, Hornung V, Jahrsd\u00f6rfer B, Blackwell S, Ballas ZK, Endres S, Krieg AM, Hartmann G (2001) Identification of CpG oligonucleotide sequences with high induction of IFN-alpha\/beta in plasmacytoid dendritic cells. Eur J Immunol 31:2154\u20132163. https:\/\/doi.org\/10.1002\/1521-4141(200107)31:7%3c2154::aid-immu2154%3e3.0.co;2-u","DOI":"10.1002\/1521-4141(200107)31:7%3c2154::aid-immu2154%3e3.0.co;2-u"},{"key":"6135_CR72","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1182\/blood-2003-04-1091","volume":"103","author":"S Rothenfusser","year":"2004","unstructured":"Rothenfusser S, Hornung V, Ayyoub M, Britsch S, Towarowski A, Krug A, Sarris A, Lubenow N, Speiser D, Endres S, Hartmann G (2004) CpG-A and CpG-B oligonucleotides differentially enhance human peptide\u2013specific primary and memory CD8+ T-cell responses in vitro. Blood 103:2162\u20132169. https:\/\/doi.org\/10.1182\/blood-2003-04-1091","journal-title":"Blood"},{"key":"6135_CR73","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1600-065X.2012.01152.x","volume":"249","author":"AT Waickman","year":"2012","unstructured":"Waickman AT, Powell JD (2012) mTOR, metabolism, and the regulation of T-cell differentiation and function. Immunol Rev 249:43\u201358. https:\/\/doi.org\/10.1111\/j.1600-065X.2012.01152.x","journal-title":"Immunol Rev"},{"key":"6135_CR74","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.cmet.2017.08.012","volume":"26","author":"PM Thwe","year":"2017","unstructured":"Thwe PM, Pelgrom LR, Cooper R, Beauchamp S, Reisz JA, D\u2019Alessandro A, Everts B, Amiel E (2017) Cell-intrinsic glycogen metabolism supports early glycolytic reprogramming required for dendritic cell immune responses. Cell Metab 26:558-567 e555. https:\/\/doi.org\/10.1016\/j.cmet.2017.08.012","journal-title":"Cell Metab"},{"key":"6135_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-78634-6","volume":"14","author":"J Zhang","year":"2024","unstructured":"Zhang J, Lin X, Yin L, Song Y, Chen X, Zhu Y, Jiang W, Lu Y, Ma Y (2024) Analyzing immune cell infiltrates in skeletal muscle of infantile-onset Pompe disease using bioinformatics and machine learning. Sci Rep 14:27485. https:\/\/doi.org\/10.1038\/s41598-024-78634-6","journal-title":"Sci Rep"},{"key":"6135_CR76","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/ni.3540","volume":"17","author":"T Chinen","year":"2016","unstructured":"Chinen T, Kannan AK, Levine AG, Fan X, Klein U, Zheng Y, Gasteiger G, Feng Y, Fontenot JD, Rudensky AY (2016) An essential role for the IL-2 receptor in Treg cell function. Nat Immunol 17:1322\u20131333. https:\/\/doi.org\/10.1038\/ni.3540","journal-title":"Nat Immunol"},{"key":"6135_CR77","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jaut.2017.07.009","volume":"84","author":"RC Ferreira","year":"2017","unstructured":"Ferreira RC, Simons HZ, Thompson WS, Rainbow DB, Yang X, Cutler AJ, Oliveira J, Castro Dopico X, Smyth DJ, Savinykh N et al (2017) Cells with Treg-specific FOXP3 demethylation but low CD25 are prevalent in autoimmunity. J Autoimmun 84:75\u201386. https:\/\/doi.org\/10.1016\/j.jaut.2017.07.009","journal-title":"J Autoimmun"},{"key":"6135_CR78","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.86850","volume":"1","author":"L Le Texier","year":"2016","unstructured":"Le Texier L, Lineburg KE, Cao B, McDonald-Hyman C, Leveque-El Mouttie L, Nicholls J, Melino M, Nalkurthi BC, Alexander KA, Teal B et al (2016) Autophagy-dependent regulatory T cells are critical for the control of graft-versus-host disease. JCI Insight 1:e86850. https:\/\/doi.org\/10.1172\/jci.insight.86850","journal-title":"JCI Insight"},{"key":"6135_CR79","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.4049\/jimmunol.1601946","volume":"198","author":"D Melis","year":"2017","unstructured":"Melis D, Carbone F, Minopoli G, La Rocca C, Perna F, De Rosa V, Galgani M, Andria G, Parenti G, Matarese G (2017) Cutting edge: increased autoimmunity risk in glycogen storage disease type 1b is associated with a reduced engagement of glycolysis in T cells and an impaired regulatory T cell function. J Immunol 198:3803\u20133808. https:\/\/doi.org\/10.4049\/jimmunol.1601946","journal-title":"J Immunol"},{"key":"6135_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05142-8","volume":"13","author":"J Wu","year":"2022","unstructured":"Wu J, Ren B, Wang D, Lin H (2022) Regulatory T cells in skeletal muscle repair and regeneration: recent insights. Cell Death Dis 13:680. https:\/\/doi.org\/10.1038\/s41419-022-05142-8","journal-title":"Cell Death Dis"},{"key":"6135_CR81","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/imcb.12040","volume":"96","author":"R Kratchmarov","year":"2018","unstructured":"Kratchmarov R, Viragova S, Kim MJ, Rothman NJ, Liu K, Reizis B, Reiner SL (2018) Metabolic control of cell fate bifurcations in a hematopoietic progenitor population. Immunol Cell Biol 96:863\u2013871. https:\/\/doi.org\/10.1111\/imcb.12040","journal-title":"Immunol Cell Biol"},{"key":"6135_CR82","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1067\/mai.2001.114238","volume":"107","author":"A Soussi-Gounni","year":"2001","unstructured":"Soussi-Gounni A, Kontolemos M, Hamid Q (2001) Role of IL-9 in the pathophysiology of allergic diseases. J Allergy Clin Immunol 107:575\u2013582. https:\/\/doi.org\/10.1067\/mai.2001.114238","journal-title":"J Allergy Clin Immunol"},{"key":"6135_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2024.101899","volume":"81","author":"S Mu\u00f1oz","year":"2024","unstructured":"Mu\u00f1oz S, Bertolin J, Jimenez V, Ja\u00e9n ML, Garcia M, Pujol A, Vil\u00e0 L, Sacristan V, Barbon E, Ronzitti G et al (2024) Treatment of infantile-onset Pompe disease in a rat model with muscle-directed AAV gene therapy. Mol Metab 81:101899. https:\/\/doi.org\/10.1016\/j.molmet.2024.101899","journal-title":"Mol Metab"},{"key":"6135_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26744-4","volume":"12","author":"H Costa-Verdera","year":"2021","unstructured":"Costa-Verdera H, Collaud F, Riling CR, Sellier P, Nordin JML, Preston GM, Cagin U, Fabregue J, Barral S, Moya-Nilges M et al (2021) Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human primates. Nat Commun 12:6393. https:\/\/doi.org\/10.1038\/s41467-021-26744-4","journal-title":"Nat Commun"},{"key":"6135_CR85","doi-asserted-by":"publisher","DOI":"10.1101\/2024.12.10.627800","author":"DD Fuller","year":"2024","unstructured":"Fuller DD, Rana S, Thakre P, Benevides E, Pope M, Todd AG, Jensen VN, Vaught L, Cloutier D, Ribas RA et al (2024) Neonatal systemic gene therapy restores cardiorespiratory function in a rat model of Pompe disease. bioRxiv. https:\/\/doi.org\/10.1101\/2024.12.10.627800","journal-title":"bioRxiv"},{"key":"6135_CR86","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/jimd.12625","volume":"47","author":"P Sellier","year":"2024","unstructured":"Sellier P, Vidal P, Bertin B, Gicquel E, Bertil-Froidevaux E, Georger C, van Wittenberghe L, Miranda A, Daniele N, Richard I et al (2024) Muscle-specific, liver-detargeted adeno-associated virus gene therapy rescues Pompe phenotype in adult and neonate Gaa(-\/-) mice. J Inherit Metab Dis 47:119\u2013134. https:\/\/doi.org\/10.1002\/jimd.12625","journal-title":"J Inherit Metab Dis"},{"key":"6135_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2025.101464","volume":"33","author":"P Sellier","year":"2025","unstructured":"Sellier P, Collaud F, Benchekroun YK, Jimenez V, Leon X, Daniele N, Pham QH, El Andari J, VandenDriessche T, Chuah MK et al (2025) A myotropic AAV vector combined with skeletal muscle cis-regulatory elements improve glycogen clearance in mouse models of Pompe disease. Mol Ther Methods Clin Dev 33:101464. https:\/\/doi.org\/10.1016\/j.omtm.2025.101464","journal-title":"Mol Ther Methods Clin Dev"},{"key":"6135_CR88","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","volume":"28","author":"H Costa Verdera","year":"2020","unstructured":"Costa Verdera H, Kuranda K, Mingozzi F (2020) AAV vector immunogenicity in humans: a long journey to successful gene transfer. Mol Ther 28:723\u2013746. https:\/\/doi.org\/10.1016\/j.ymthe.2019.12.010","journal-title":"Mol Ther"},{"key":"6135_CR89","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1056\/NEJMc2212912","volume":"388","author":"CG Bonnemann","year":"2023","unstructured":"Bonnemann CG, Belluscio BA, Braun S, Morris C, Singh T, Muntoni F (2023) Dystrophin immunity after gene therapy for Duchenne\u2019s muscular dystrophy. N Engl J Med 388:2294\u20132296. https:\/\/doi.org\/10.1056\/NEJMc2212912","journal-title":"N Engl J Med"},{"key":"6135_CR90","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1172\/JCI16887","volume":"111","author":"F Mingozzi","year":"2003","unstructured":"Mingozzi F, Liu YL, Dobrzynski E, Kaufhold A, Liu JH, Wang Y, Arruda VR, High KA, Herzog RW (2003) Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest 111:1347\u20131356. https:\/\/doi.org\/10.1172\/JCI16887","journal-title":"J Clin Invest"},{"key":"6135_CR91","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1182\/blood-2007-03-080093","volume":"110","author":"F Mingozzi","year":"2007","unstructured":"Mingozzi F, Hasbrouck NC, Basner-Tschakarjan E, Edmonson SA, Hui DJ, Sabatino DE, Zhou S, Wright JF, Jiang H, Pierce GF et al (2007) Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood 110:2334\u20132341. https:\/\/doi.org\/10.1182\/blood-2007-03-080093","journal-title":"Blood"},{"key":"6135_CR92","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cellimm.2015.10.001","volume":"301","author":"X Wang","year":"2016","unstructured":"Wang X, Terhorst C, Herzog RW (2016) In vivo induction of regulatory T cells for immune tolerance in hemophilia. Cell Immunol 301:18\u201329. https:\/\/doi.org\/10.1016\/j.cellimm.2015.10.001","journal-title":"Cell Immunol"},{"key":"6135_CR93","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1111\/j.1538-7836.2011.04351.x","volume":"9","author":"B Moghimi","year":"2011","unstructured":"Moghimi B, Sack BK, Nayak S, Markusic DM, Mah CS, Herzog RW (2011) Induction of tolerance to factor VIII by transient co-administration with rapamycin. J Thromb Haemost 9:1524\u20131533. https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04351.x","journal-title":"J Thromb Haemost"},{"key":"6135_CR94","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1016\/j.ymthe.2022.07.005","volume":"30","author":"JSS Butterfield","year":"2022","unstructured":"Butterfield JSS, Yamada K, Bertolini TB, Syed F, Kumar SRP, Li X, Arisa S, Pi\u00f1eros AR, Tapia A, Rogers CA et al (2022) IL-15 blockade and rapamycin rescue multifactorial loss of factor VIII from AAV-transduced hepatocytes in hemophilia A mice. Mol Ther 30:3552\u20133569. https:\/\/doi.org\/10.1016\/j.ymthe.2022.07.005","journal-title":"Mol Ther"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-026-06135-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-026-06135-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-026-06135-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T01:20:02Z","timestamp":1775265602000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-026-06135-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6135"],"URL":"https:\/\/doi.org\/10.1007\/s00018-026-06135-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7329159\/v1","asserted-by":"object"}]},"ISSN":["1420-9071"],"issn-type":[{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Federico Mingozzi and Giuseppe Ronzitti are inventors in patents applications concerning the treatment of Pompe disease by AAV licensed to Spark Therapeutics (WO2018046774, WO2018046775, WO2018046775). Federico Mingozzi is a former employee of Spark Therapeutics. Helena Costa-Verdera is a current employee of Spark Therapeutics. All other authors have no relevant interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"191"}}